In addition, a study by Zhong et al. found that METTL3/m6A participates in AAA formation by promoting the expression of mature miR34a, thereby reducing the expression of SIRP1, providing new targets and diagnostic biomarkers for clinical treatment of AAA (115). This evidence concerns the gene METTL3 and triple-A syndrome.